family with sequence similarity 30 member BGenealiases: HsT16028 · KIAA0125P1
Q-omics provides the consensus-scored FAM30B profile across patient tissues and cancer cell-line models. FAM30B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM30B is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, FAM30B RNA expression shows 3,802 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight KIRC, PRAD, and COAD as cancer lineages where FAM30B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM30B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM30B survival associations across molecular data types. FAM30B RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM30B RNA expression–survival associations across cancer types. High FAM30B expression shows unfavorable associations in KIRC, MESO, CHOL, COAD, THCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM30B RNA expression.
This table summarizes FAM30B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM30B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM30B shows higher tumor expression in PRAD. The PRAD box plot shows higher FAM30B RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .015).
This table shows molecular features associated with FAM30B in patient tissues and cancer cell lines. In patient samples, FAM30B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
